MAR 0 6 2006

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO 10/554,702 Application Number INFORMATION DISCLOSURE Filing Date October 27, 2005 STATEMENT BY APPLICANT Olivier Bezencon First Named Inventor Art Unit (Use as many sheets as necessary) Not Yet Assigned Examiner Name A0345.00165 2 Attorney Docket Number 1 Sheet

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KV	AA	US-5,380,758	0 - 10-1995		
KΝ	AB	US-5,703,073	2-30-1997		

			FOREIG	GN PATENT	DOCUMENTS		
Examiner Initials*	Ι,		Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Cite No.1	Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)				T°
KV	(B	A	WO-97/27749	08-07-1997	Nitromed Inc.		
7	В	В	WO-98/19672	05-14-1998	Nitromed Inc.		L
	В	C	WO-98/21193	05-22-1998	Nicox S.A.		L
1	В	П	WO-99/00361	01-07-1999	Nicox S.A.		
	В	E•	WO-97/09311-				
	В	F*	WO-03/093267				
		G.	WO-04/002937				上

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. \Applicant's unique citation designation number (optional). \(^2\) See Kinds Codes of USPTO Patent Documents at \(\frac{\text{www.uspto.gov}}{\text{www.uspto.gov}}\) or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^3\) Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. \(^6\) Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
KN	CA Von Dietrich Jerchel, et al., "N-METHYL-OXA-GRANATOLIN," Justus Liebigs Ann. Chem., (1957), Bd. 607, pp. 126-131				
KM	CB Charles L. Zirkle, et al., "THE ISOMERIC 3-OXA-AND3-THIAGRANATANIN-7-OLS AND THEIR DERIVATIVES; REDUCTION OF BICYCLIC AMINO KETONES RELATED TO TROPINONE," Reduction of Bicyclic Amino Ketones Related to Tropinone, (1961), pp. 395-407				
KM	Jan Epsztajn, et al., "APPLICATION OF ORGANOLITHIUM AND RELATED REAGENTS IN SYNTHESIS. PART 7 ¹ . SYNTHESIS AND METALLATION OF 4-METHOXYPICOLIN-AND 2-METHOXYISONICOTIN-ANILIDES. A USEFUL METHOD FOR PREPARATION OF 2,3,4-TRISUBSTITUTED PYRIDINES," (1989) Tetrahdron, vol. 45, pp. 7469-7476				
KN	CD				
KH	CE	Daniel L. Comins, et al., "REGIOSPECIFIC α-ALKYLATION OF 4- CHLORO(BROMO)PYRIDINE," J. Org. Chem., (1985), pp. 4410-4411			
	CF*	Waeber B., et al., "THE RENIN-ANGIOTENSIN SYSTEM IN EXPERIMENTAL AND HUMAN HYPERTENSION", fir Berkenhager W.H. Reid J.L. (eds): Hypertension, Amsterdam, Elsevier			
		Science Publishing Co., (1996), pp. 489-519			
	co.				
	CH*	Rosenberg, M.E., et al., Kidney International, (1994), 45, 403 Breyter, J.A., et al., Kidney International, (1994), 45, S156			
Examine			_		
Signature			ナ		

DOCSNY.185464.1



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

eduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/B/PTO 10/554,702 Application Number **INFORMATION DISCLOSURE** October 27, 2005 Filing Date Olivier Bezencon STATEMENT BY APPLICANT First Named Inventor Art Unit (Use as many sheets as necessary) Not Yet Assigned K. Hab Je Examiner Name 2 2 A0345.00165 Sheet Attorney Docket Number

		1		
		$7 \square$	CJ+	Vaughan, D.E., et al., Cardiovasc. Res., (1994), 28, 159
			CK*	Fouad-Tarazi, F., et al., Am. J. Med., (1988), 84 (Suppl. 3A), 83
			CL.	Pfeffer, M.A., et al., N. Engl. J. Med., (1992), 327, 669
			CM*	Kleinert, H.D., Cardiovasc. Drugs, (1995), 9, 645
-			CN*	Husain, A., J. Hypertens, (1993), 11, 1155
			CO.	Israili Z.H., et al., Annals of Internal Medicine, (1992), 117, 234
			CP****	Azizi M., et al., J. Hypertens., (1994) 12, 419
			CQ*	Neutel, J.M., et al., Am. Heart, (1991), 122, 1094
\subseteq	P		CR*	Rahuel, Jr., et al., Chem. Biol., (2000), 7, 493
	H		CS*	Mealy, N.E., Drugs of the Future, (2001) 26, 1139
نسا	H		CT*	Ωefner, C., et al., Chem. Biol., (1999), 6, 127
	H		CU*	Marki, H.P., et al., Il Farmaco, (2001), 56, 21
			CV*	Majewski, M., et al., J. Org. Chem., (1995) 60, 5825
_		1	CW*	Kiesewetter, D.O., Tetrahedron Asymmetry, (1993) 4, 2183

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached